Question 1

What are the differences between denosumab and zoledronic acid in terms of side effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer clinical trial (NCT00321620). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my response to treatment be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer clinical trial (NCT00321620). Contact the study team or your healthcare provider for specific answers.

Question 3

What happens if I experience side effects from the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer clinical trial (NCT00321620). Contact the study team or your healthcare provider for specific answers.

Question 4

How long will I need to participate in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer clinical trial (NCT00321620). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer clinical trial (NCT00321620). Contact the study team or your healthcare provider for specific answers.

Question 6

What are the potential benefits of participating in this study for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer clinical trial (NCT00321620). Contact the study team or your healthcare provider for specific answers.

What this study is about